Pharmacare deal can’t be ‘massively expensive,’ minister says as clock ticks

The health minister says he's confident that pharmacare legislation will meet the March 1 deadline with the NDP, but he says it cannot be a 'massively expensive program.'

Health Minister Mark Holland says the government must be respectful of “a challenging fiscal framework” where Ottawa can’t spend “an enormous amount of money” in trying to strike a deal on pharmacare.

This comes as NDP Leader Jagmeet Singh has redrawn a line in the sand in the confidence and supply agreement with the Liberals, saying if a pharmacare bill is not introduced by the March 1 deadline he considers the agreement broken.

“We can’t afford this to be a massively expensive program. We’re not in a time where the fiscal framework can absorb massive costs. And so that absolutely is a consideration,” Holland said on his way out of cabinet Tuesday.

“We’re looking at how to make drugs more affordable for Canadians and how to take definitive action, but be respectful of the challenging fiscal framework that we’re in. We’re not in a time where we can just open up and spend an enormous amount of money. So, there are points of difference on issues like that.”

The minister adds that what will ultimately be introduced at this step is framework legislation for a pharmacare program.

According to an estimate from the Parliamentary Budget Officer (PBO), the total federal and provincial expenditure in a universal pharmacare program would be $33.2 billion in the 2024-25 fiscal year, growing to $38.9 billion over the next four years.

A model based on Quebec’s drug plan being expanded nationally would cost the public sector $11.2 billion in 2024-25, growing to $13.4 billion in 2027-28 according to the PBO.

The PBO notes in its modeling there is no way to isolate federal spending from provincial funds.